

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information only and does not constitute an invitation or offer to accept, purchase or subscribe for any securities of the Company.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “**U.S. Securities Act**”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*



HOME CONTROL INTERNATIONAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1747)

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Sole Placing Agent and Sole Overall Coordinator



Reference is made to the announcement of Home Control International Limited (the “**Company**”) dated 18 November 2025 in respect of the Placing (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

COMPLETION OF PLACING

The Board is pleased to announce that all the conditions of the Placing Agreement have been satisfied and that the completion of the Placing took place on 25 November 2025.

A total of 28,424,000 Placing Shares, representing approximately 5.31% of the issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately upon completion of the Placing, have been successfully placed to not less than six Placees at the Placing Price of HK\$3.80 per Placing Share pursuant to the terms and conditions of the Placing Agreement. To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, the Placees and their respective ultimate beneficial owners are Independent Third Parties. None of the Placees became a substantial shareholder (as defined under the Listing Rules) of the Company upon completion of the Placing.

USE OF PROCEEDS FROM THE PLACING

The proceeds from the Placing are intended to be applied towards the new business segment of the Company, namely healthcare solutions, which the Group has decided to expand into in view of the growing demand for healthcare and promising market potential demonstrated in recent years. The Group intends to leverage its expertise in IoT technology utilized in its existing business of smart remote control solutions and introduce AI elements to develop innovative AIoT technology dedicated to personal healthcare management. For this purpose, the Group will launch a new brand focusing on the development of AIoT-enabled home healthcare platforms, ecosystems and healthcare management products and the provision of healthcare operation services, integrating hardware, devices, software, data and services. For further details, please refer to the voluntary announcements of the Company dated 12 September 2025 and 25 September 2025. The Group will continue to operate, and has no intention to dispose of, downsize or terminate, its existing business of home control solutions.

In addition to the above and the information disclosed in the Announcement, the Board wishes to provide the Shareholders and potential investors of the Company with the following additional information regarding the use of proceeds from the Placing:

- (1) Approximately 70% of the net proceeds will be used to fund research and development activities in connection with the Group's healthcare-related business initiatives. Further details are set out as follows:

Intended usage	Development plan	Approximate amount (HKD million)	Approximate percentage of total net proceeds	Expected timeline for utilization of the net proceeds
Development of AIoT technologies (leveraging its existing expertise in IoT technology) and products, which are built upon an AI-powered platform supported by the personal health agent, an interactive digital twin application that can be connected with multiple personal healthcare devices and enable data interaction. By collecting, analysing and monitoring personal healthcare data and projecting a digital image of the user based on such data, the personal health agent can track real-time updates to the user's health condition and provide healthcare related analysis and advice via devices or cloud platforms.	• Milestone 1 To complete the preliminary planning and setup of a structured pathology-centric medical knowledge base with secure pipelines for collecting, annotating and labeling multimodal health data and the development of an agentic framework that bridges device data, medical knowledge and user intent	15.95	15%	By 31 March 2026
	• Milestone 2 To develop the first full prototype of the personal health agent and integrate user interaction, real-time monitoring and personalized coaching functions	37.21	35%	By 30 August 2026
We aim to achieve the above through measures including but not limited to the establishment of joint ventures and contractual relationships with core partners (such as experts, research institutions and technology partners).				

Intended usage	Development plan	Approximate amount (HKD million)	Approximate percentage of total net proceeds	Expected timeline for utilization of the net proceeds
Development and integration of core personal healthcare management products (including but not limited to digital interactive health gadgets and health devices in home healthcare scenarios such as health monitoring rings and smart medicine boxes etc.) through in-house development, outsourced development and strategic collaborations	Milestone 1 To complete the selection and preliminary validation of key components, establish low-power reference designs and lightweight embedded operating systems and define secure hardware-software interfaces for personal healthcare management products	10.63	10%	By 31 March 2026
	Milestone 2 To deliver the first integrated beta hardware prototype of personal healthcare devices in both wearable and home hub forms and complete preliminary safety testing and basic regulatory preparatory work appropriate for consumer healthcare products	10.63	10%	By 30 August 2026

- (2) Approximately 20% of the net proceeds will be used to support the implementation and operations of the Group's healthcare-related business. Further details are set out as follows:

Intended usage	Development plan	Approximate amount (HKD million)	Approximate percentage of total net proceeds	Expected timeline for utilization of the net proceeds
Strategic collaboration with industry and cross industry partners	To engage in strategic collaborations with industry and cross-industry partners to support the optimization of procurement, manufacturing, production, branding, marketing and distribution channels	15.95	15%	By 30 November 2026
Engagement of consulting service providers	To engage external consulting service providers to conduct industry research, business analysis, compliance management and to build business resource connections in the healthcare domain	5.32	5%	By 30 November 2026

- (3) Approximately 10% of the net proceeds will be used to supplement working capital and for general corporate purposes. Further details are set out as follows:

Intended usage	Approximate amount (HKD million)	Approximate percentage of total net proceeds	Expected timeline for utilization of the net proceeds
Staff costs of Orbiva (as defined below) (including salary, bonus and other incentives) for an initial team of 5-10 employees	7.44	7%	By 30 November 2026
Office rent and other operating expenses and staff accommodation costs of Orbiva	2.13	2%	By 30 November 2026
Professional fees (including fees for engaging external company secretary, legal counsel and financial service providers) and other administrative expenses	1.06	1%	By 30 November 2026

The net proceeds as set out in (1) above are intended to fund the research development activities for specific healthcare-related technologies and products under the offering portfolio of Orbiva Limited (“**Orbiva**”), the wholly-owned subsidiary of the Company established for the purpose of facilitating the Group’s healthcare-related business, while the net proceeds as set out in (2) above are intended to be applied towards the production and marketing activities and general business development of Orbiva.

On 14 November 2019, the shares of the Company were listed on the Main Board of the Stock Exchange and the net proceeds raising from the initial public offering after deducting underwriting fees and other related listing expenses amounted to approximately HK\$84.93 million (equivalent to approximately US\$10.83 million) (“**IPO Proceeds**”). As of 30 June 2025, the Company had unutilized IPO Proceeds in the amount of approximately US\$2.72 million, of which US\$0.39 million will be used for expansion of professional sales force to support business expansion, and approximately US\$2.33 million will be used for working capital and general corporate purposes. While the unutilized IPO Proceeds allocated for working capital and general corporate purposes were intended to be applied towards the Group’s original business of the provision of home control solutions primarily operated through the Group’s headquarters in Singapore, as the Group has since expanded a new business segment in the healthcare sector and incorporated Orbiva in September 2025 as a new subsidiary in Hong Kong, the Company expects that further funds will be required to meet the daily administrative needs of establishing and maintaining Orbiva, for which the net proceeds as set out in (3) have been allocated.

We have placed the unutilized IPO Proceeds, and will place the net proceeds from the Placing, as short-term deposits in interest-bearing accounts at licensed commercial banks and/or authorized financial institutions.

EFFECTS OF THE PLACING ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

To the best of the Directors’ knowledge, information and belief after having made all reasonable enquiries, the shareholding structure of the Company immediately before and after completion of the Placing is set out below:

Shareholder	Immediately before the Placing		Immediately after completion of the Placing	
	Number of Shares	Approximate % (Note 1)	Number of Shares	Approximate % (Note 1)
Meta-Wisdom (Note 2)	375,202,000	74.06	375,202,000	70.12
Mr. Kwok Hoong SIU (Note 3)	501,634	0.10	501,634	0.09
Mr. Alain PERROT (Note 4)	84	0.00	84	0.00
Public Shareholders				
Placees	–	–	28,424,000	5.31
Other Shareholders	130,946,282	25.85	130,946,282	24.47
Total	506,650,000	100.00	535,074,000	100.00

Notes:

- (1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.
- (2) Meta-Wisdom is an investment holding company and its issued share capital is beneficially owned as to 1% by Wisdom Tech Innovation Limited and 99% by O-sycamore Holdings Limited. Wisdom Tech Innovation Limited is an investment holding company wholly-owned by Mr. YANG Haofang (“**Mr. YANG**”). O-sycamore Holdings Limited is an investment holding company wholly-owned by the Thomethan Settlement. The Thomethan Settlement is a discretionary trust established by Mr. YANG as settlor, the discretionary beneficiaries of which are family members of Mr. YANG. Mr. YANG is an executive Director of the Company.
- (3) Mr. Kwok Hoong SIU is an executive Director and the chief executive officer of the Company.
- (4) Mr. Alain PERROT is a non-executive Director and the chairman of the Board.

By Order of the Board
Home Control International Limited
Kwok Hoong SIU
Chief Executive Officer and Executive Director

Hong Kong, 25 November 2025

As of the date of this announcement, the Board comprises Mr. Kwok Hoong SIU and Mr. Haofang YANG as executive Directors; Mr. Alain PERROT and Ms. Ying MA as non-executive Directors; and Mr. Werner Peter VAN ECK, Dr. Shou Kang CHEN, Ms. Keet Yee LAI, Mr. Min YE and Mr. Yi Chung CHEN as independent non-executive Directors.